AMRI Promotes Takeshi Yura, Ph.D., to Vice President of Discovery and
Development Services, Asia
ALBANY, New York, Feb. 25, 2013
-- Integrated Leadership of Singapore and India Strengthens SMARTSOURCING™
ALBANY, New York, Feb. 25, 2013 /PRNewswire/ -- AMRI announced today that it
has promoted Takeshi Yura, Ph.D., to Vice President of Discovery and
Development Services, Asia. Dr. Yura will report directly to Thomas E.
D'Ambra, Ph.D., Chairman, President and CEO.
(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )
Dr. Yura joined AMRI in January 2011 and most recently served as Senior
Director of Drug Discovery services in Singapore, leading the chemistry and
biology teams of AMRI's flagship Asian integrated drug discovery operations.
Effective immediately, Dr. Yura has also assumed leadership of AMRI's
Discovery and Development efforts at AMRI's Hyderabad, India site.
Dr. D'Ambra said, "AMRI's Singapore and Hyderabad operations are important and
growing businesses for AMRI and conduct projects for customers located all
over the world. With the ongoing evolution of outsourcing and a growing focus
from customers on strategic relationships, we believe that Dr. Yura's
leadership, his focus on excellence in scientific research and his dedication
to quality and the integrity of our customers' intellectual property will
provide integration under one leadership of what we are referring to as 'AMRI
Asia.' This new alignment will enable seamless transfer and execution of
projects within and between sites to consistent high standards and provide
more effective project management and development of key talent."
Dr. D'Ambra added, "We have a growing international customer base in Singapore
that has been looking to utilize the synergies of that location with our
custom library, discovery chemistry, development, analytical and kilo scale
capabilities at Hyderabad. When you also consider our large scale
manufacturing capabilities in Aurangabad, AMRI Asia is now equipped to
seamlessly serve our customers from early discovery to large scale production
in this newest application of our SMARTSOURCING™ strategy."
Dr. Yura brings to this role more than 22 years of scientific and leadership
experience in discovery research, project management and business development.
Before joining AMRI, he was a director at Dishman Japan Ltd., responsible for
sales and all business development activities for contract manufacturing
services. Before that, he served as discovery chemistry research head at
Pfizer Japan, dedicated primarily to the areas of pain and gastrointestinal
drug discovery. Prior to Pfizer, he served as section head, medicinal
chemistry at Bayer Yakuhin in Japan focused on urology and asthma. He has held
additional scientific roles at both Ciba Geigy Japan and Tanabe Seiyaku. Dr.
Yura obtained a Ph.D. in synthetic organic chemistry at the University of
Tokyo, working with Professor Teruaki Mukaiyama until his retirement and with
Professor Koichi Narasaka. He also holds an M.B.A. from the Temple University
About AMRI Albany Molecular Research, Inc. (AMRI) is a global contract
research and manufacturing organization offering customers fully integrated
drug discovery, development and manufacturing services. For over 21 years,
AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology
industries have undergone tremendous change in response to multiple
challenges. This experience, a track record of success and locations in the
United States, Europe and Asia now provides our customers with SMARTSOURCING™,
a full range of value-added opportunities providing customers informed
decision-making, enhanced efficiency and more successful outcomes at all
stages of the pipeline. AMRI has also successfully partnered R&D programs and
is actively seeking to out-license its remaining programs for further
development. For more information about AMRI, please visit our website at
www.amriglobal.com or follow us on Twitter (@amriglobal).
About Singapore Research Centre, Pte. Ltd. In Singapore, AMRI provides
integrated chemistry and biology services to support drug discovery programs.
The Singapore site specializes in all medicinal chemistry services, such as
hit-to-lead and lead optimization services, and also serves as AMRI's global
biology center. In the area of biology/ in vitro pharmacology, the Centre
provides target validation; assay development; HTS; rapid production of SAR
quality data; and in vitro ADMET support, including CYP inhibition, metabolic
stability (liver microsome assays), and aqueous solubility. As a signatory to
the World Patent Treaty, Singapore provides an environment that stringently
protects intellectual property, enabling our scientists to conduct proprietary
and cutting-edge research on behalf of our customers.
About AMRI India Operations In India, AMRI offers cost-competitive chemical
synthesis and kilo lab work, as well as a reliable, large-scale manufacturing
source for starting materials and intermediates. AMRI established its presence
in India in 2007. Since that time, capabilities have been built in the areas
of chemical synthesis and manufacturing, keeping AMRI's core values of Safety,
Quality and Customer Satisfaction and Service at the forefront of the
Company's business objectives. Today, AMRI in India has significant
capabilities and capacity across the Custom Research and Manufacturing
Services (CRAMS) space. AMRI's Global Project Management Team has access to
the extensive experience and capabilities of all of the Company's global
locations, and can tap into the collective problem solving and brainpower of
industry experienced managers as needed. Numerous projects are in progress or
have been completed using this integrated model, and AMRI's operations in
Hyderabad and Aurangabad, India, are especially well-suited to be a
centerpiece of a global project team.
Contact: Investors: Michael Nolan, AMRI Chief Financial Officer,
+1-518-512-2261; Media: Gina Monari, AMRI Communications, +1-518-512-2512
Press spacebar to pause and continue. Press esc to stop.